152 related articles for article (PubMed ID: 34258542)
1. Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series.
Matsuo T; Nakamura T; Sato K; Miyata Y; Sakai H
IJU Case Rep; 2021 Jul; 4(4):251-254. PubMed ID: 34258542
[TBL] [Abstract][Full Text] [Related]
2. Prosultiamine for treatment of lower urinary tract dysfunction accompanied by human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis.
Matsuo T; Miyata Y; Nakamura T; Satoh K; Sakai H
Int J Urol; 2018 Jan; 25(1):54-60. PubMed ID: 28965354
[TBL] [Abstract][Full Text] [Related]
3. Clinical course of neurogenic bladder dysfunction in human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: a nationwide registry study in Japan.
Iijima N; Yamauchi J; Yagishita N; Araya N; Aratani S; Tanabe K; Sato T; Takata A; Yamano Y
Orphanet J Rare Dis; 2021 Aug; 16(1):355. PubMed ID: 34372895
[TBL] [Abstract][Full Text] [Related]
4. Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis.
Yamakawa N; Yagishita N; Matsuo T; Yamauchi J; Ueno T; Inoue E; Takata A; Nagasaka M; Araya N; Hasegawa D; Coler-Reilly A; Tsutsumi S; Sato T; Araujo A; Casseb J; Gotuzzo E; Jacobson S; Martin F; Puccioni-Sohler M; Taylor GP; Yamano Y;
Orphanet J Rare Dis; 2020 Jul; 15(1):175. PubMed ID: 32620176
[TBL] [Abstract][Full Text] [Related]
5. Oral phenazopyridine vs intravesical lidocaine for bladder onabotulinumtoxinA analgesia: a randomized controlled trial.
Stewart LE; Siddique M; Jacobs KM; Raker CA; Sung VW
Am J Obstet Gynecol; 2022 Aug; 227(2):308.e1-308.e8. PubMed ID: 35580634
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of mirabegron for overactive bladder with human T cell lymphotropic virus-1 associated myelopathy.
Matsuo T; Miyata Y; Nakamura T; Satoh K; Sakai H
Low Urin Tract Symptoms; 2019 Apr; 11(2):O65-O70. PubMed ID: 29473309
[TBL] [Abstract][Full Text] [Related]
7. Urodynamic Outcomes in Children after Single and Multiple Injections for Overactive and Low Compliance Neurogenic Bladder Treated with Abobotulinum Toxin A.
Naqvi S; Clothier J; Wright A; Garriboli M
J Urol; 2020 Feb; 203(2):413-419. PubMed ID: 31518199
[TBL] [Abstract][Full Text] [Related]
8. The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy.
Carneiro Neto JA; Bittencourt VG; de Oliveira C; Andrade R; Carvalho EM
Rev Soc Bras Med Trop; 2014 Jul; 47(4):528-32. PubMed ID: 25229299
[TBL] [Abstract][Full Text] [Related]
9. Probable HTLV-I/II Tropical Spastic Paraparesis Patient from Ethiopia: A Case Report.
Melka D; Zebenigus M
Ethiop J Health Sci; 2022 Jul; 32(4):865-868. PubMed ID: 35950079
[TBL] [Abstract][Full Text] [Related]
10. Inconsistency in the Definition of Urinary Tract Infection after Intravesical Botulinum Toxin A Injection: A Systematic Review.
Stamm AW; Adelstein SA; Chen A; Lucioni A; Kobashi KC; Lee UJ
J Urol; 2018 Oct; 200(4):809-814. PubMed ID: 29653162
[TBL] [Abstract][Full Text] [Related]
11. An update on human T-cell leukemia virus type I (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) focusing on clinical and laboratory biomarkers.
Yamauchi J; Araya N; Yagishita N; Sato T; Yamano Y
Pharmacol Ther; 2021 Feb; 218():107669. PubMed ID: 32835825
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie J; Wilson DI; Herbison GP; Wilson D
Cochrane Database Syst Rev; 2007 Jul; (3):CD005493. PubMed ID: 17636801
[TBL] [Abstract][Full Text] [Related]
13. Adding mirabegron after intravesical onabotulinumtoxinA injection improves therapeutic effects in patients with refractory overactive bladder.
Wang CC; Lee CL; Hwang YT; Kuo HC
Low Urin Tract Symptoms; 2021 Oct; 13(4):440-447. PubMed ID: 33960119
[TBL] [Abstract][Full Text] [Related]
14. Human T-Lymphotropic Virus-1-Associated Myelopathy/Tropical Spastic Paraparesis Is Associated With Sexual Dysfunction in Infected Women of Reproductive Age.
Lopes Martins AL; Rios Grassi MF; de Aquino Firmino A; Lacerda Araujo JP; Paixao TS; Galvão-Castro B; Boa-Sorte N
Sex Med; 2018 Dec; 6(4):324-331. PubMed ID: 30181035
[TBL] [Abstract][Full Text] [Related]
15. Higher Neural Correlates in Patients with Multiple Sclerosis and Neurogenic Overactive Bladder Following Treatment with Intradetrusor Injection of OnabotulinumtoxinA.
Khavari R; Elias SN; Pande R; Wu KM; Boone TB; Karmonik C
J Urol; 2019 Jan; 201(1):135-140. PubMed ID: 30076906
[TBL] [Abstract][Full Text] [Related]
16. Bladder instillation of liposome encapsulated onabotulinumtoxina improves overactive bladder symptoms: a prospective, multicenter, double-blind, randomized trial.
Chuang YC; Kaufmann JH; Chancellor DD; Chancellor MB; Kuo HC
J Urol; 2014 Dec; 192(6):1743-9. PubMed ID: 25046622
[TBL] [Abstract][Full Text] [Related]
17. A refractory human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia/lymphoma: A case report and review of the literature.
Tamaki K; Mera H; Takeshita S; Fujioka S; Goto M; Matsumoto T; Yamano Y; Takamatsu Y; Tsuboi Y
Medicine (Baltimore); 2021 Oct; 100(40):e27450. PubMed ID: 34622865
[TBL] [Abstract][Full Text] [Related]
18. Retrospective clinic and urodynamic study in the neurogenic bladder dysfunction caused by human T cell lymphotrophic virus type 1 associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Troisgros O; Barnay JL; Darbon-Naghibzadeh F; Olive P; René-Corail P
Neurourol Urodyn; 2017 Feb; 36(2):449-452. PubMed ID: 26756420
[TBL] [Abstract][Full Text] [Related]
19. Intravesical Instillation of OnabotulinumtoxinA in the Treatment of Refractory Overactive Bladder in Participants with Urinary Incontinence.
Chermansky CJ; Richter HE; Jacoby K; Titanji W; Jenkins B; Geib T; Brucker BM
J Urol; 2022 Oct; 208(4):855-862. PubMed ID: 35830550
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin injections for adults with overactive bladder syndrome.
Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
